SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

R Campo, E DeJesus, U F Bredeek, K Henry, H Khanlou, K Logue, C Brinson, P Benson, L Dau, H Wang, K White, J Flaherty, T Fralich, B Guyer, D Piontkowsky, R Campo, E DeJesus, U F Bredeek, K Henry, H Khanlou, K Logue, C Brinson, P Benson, L Dau, H Wang, K White, J Flaherty, T Fralich, B Guyer, D Piontkowsky

Abstract

Background: In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alternative. For patients infected with human immunodeficiency virus (HIV-1) virologically suppressed on a boosted protease inhibitor (PI) + 3TC/ABC regimen, the merits of switching to FTC/TDF as the NRTI backbone are unknown.

Methods: SWIFT was a prospective, randomized, open-label 48-week study to evaluate efficacy and safety of switching to FTC/TDF. Subjects receiving 3TC/ABC + PI + ritonavir (RTV) with HIV-1 RNA < 200 c/mL ≥3 months were randomized to continue 3TC/ABC or switch to FTC/TDF. The primary endpoint was time to loss of virologic response (TLOVR) with noninferiority measured by delta of 12%. Virologic failure (VF) was defined as confirmed rebound or the last HIV-1 RNA measurement on study drug ≥200 c/mL.

Results: In total, 311 subjects were treated in this study (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC). Baseline characteristics were similar between the arms: 85% male, 28% black, median age, 46 years; and median CD4 532 cells/mm(3). By TLOVR through week 48, switching to FTC/TDF was noninferior compared to continued 3TC/ABC (86.4% vs 83.3%, treatment difference 3.0% (95% confidence interval, -5.1% to 11.2%). Fewer subjects on FTC/TDF experienced VF (3 vs 11; P = .034). FTC/TDF showed greater declines in fasting low-density lipoproteins (LDL), total cholesterol (TC), and triglycerides (TG) with significant declines in LDL and TC beginning at week 12 with no TC/HDL ratio change. Switching to FTC/TDF showed improved NCEP thresholds for TC and TG and improved 10-year Framingham TC calculated scores. Decreased estimated glomerular filtration rate [corrected] (eGFR) was observed in both arms with a larger decrease in the FTC/TDF arm.

Conclusions: Switching to FTC/TDF from 3TC/ABC maintained virologic suppression, had fewer VFs, improved lipid parameters and Framingham scores but decreased eGFR. CLINICALTRIALS.GOV IDENTIFIER: NCT00724711.

Keywords: 3TC/ABC; FTC/TDF; HIV-1; switch; virologic failure.

Figures

Figure 1.
Figure 1.
Virologic response and virologic failure by Kaplan-Meier through week 48.
Figure 2.
Figure 2.
Fasting total cholesterol and triglycerides by National Cholesterol Education Program classification.
Figure 3.
Figure 3.
Categorical shifts by Framingham 10-year risk scores from baseline to week 48.

References

    1. Department of Health and Human Services (DHHS) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. Available at .
    1. Martinez E, Arranz JA, Podzamczer D, et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study [oral presentation] 2007 Paper presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS). Sydney, Australia, July 22–26.
    1. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230–40.
    1. Valantin MA, Bittar R, de Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010;65:556–61.
    1. Behrens G, Maserati R, Rieger A, et al. Switching from kivexa [ABC/3TC ]+kaletra [LPV/r] to truvada [TDF/FTC]+kaletra [LPV/r] reduces high hholesterol: results of a 12 week randomized, controlled study (ROCKET II) [Poster WEPE0110] 2010 Poster presented at: XVIII International AIDS Conference. Vienna, Austria, July 18–23.
    1. Moyle G, Orkin C, Fisher M, et al. Switching from kivexa (KVX) + efavirenz (EFV) to atripla (ATR) reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, andomised study [poster P80] 2010 Poster presented at: 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 7–11.
    1. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30.
    1. SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–24.
    1. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228–38.
    1. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Relation between use of nucleosidic reverse transcriptase inhibitors (NRTI) and risk of acute myocardial infarction (AMI): a nested case control study using Quebec's public health insurance database (RAMQ)[poster] 2009 Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, July 19–22.
    1. Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P. Abacaviruse and risk of acute myocardial infarction and cerebrovascular disease in the HAART era [oral presentation] 2009 Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19–22.
    1. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55:615–9.
    1. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441–7.
    1. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel. Ann Intern Med. 2012;156:817–33.
    1. Framingham Heart Study. A Project of the National heart, lung, and blood institute and Boston University. Available at . Accessed 3 January 2012.
    1. National Cholesterol Education Program (NCEP) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Executive Summary. 2001
    1. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009;51:3–6.
    1. Damond F, Roquebert B, Benard A, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol. 2007;45:3436–38.
    1. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57.
    1. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155–63.
    1. Madruga JV, Cassetti I, Etzel A, et al. The 10-year safety and efficacy of tenofovir DF (TDF)-containing HAART in antiretroviral naive patients [poster P086] 2010 Poster presented at: 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 7–11.
    1. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2012

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren